Bevirimat

From WikiMD.org
Jump to navigation Jump to search

Bevirimat

Bevirimat (pronunciation: be-vi-ri-mat) is an experimental antiretroviral drug that was under development for the treatment of HIV infection. It belongs to a class of drugs known as maturation inhibitors, which work by preventing the virus from reaching its mature, infectious form.

Etymology

The name "Bevirimat" is derived from the words "bevi" and "mat", which are abbreviations for "beverage" and "maturation" respectively. This is a reference to the drug's method of administration (as a liquid) and its mechanism of action (inhibiting the maturation of the HIV virus).

Mechanism of Action

Bevirimat works by binding to the Gag protein, a key component of the HIV virus. This prevents the Gag protein from being cleaved into its final components, thus stopping the virus from maturing and becoming infectious.

Development and Clinical Trials

Bevirimat was developed by Panacos Pharmaceuticals, a biotechnology company based in the United States. It underwent Phase II clinical trials, but development was halted in 2010 due to issues with drug formulation and patient response.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski